| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NCT05252390) | Nuvation Bio Inc. | 2022-03-29 |
| A Study of PRT2527 in Participants With Advanced Solid Tumors (NCT05159518) | Prelude Therapeutics | 2022-02-14 |
| PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer (NCT04768608) | Zhejiang University | 2021-12-23 |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide (NCT04335682) | Alliance Foundation Trials, LLC. | 2021-08-17 |
| Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer (NCT04737109) | David VanderWeele | 2021-07-13 |
| Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (NCT04319783) | Trans Tasman Radiation Oncology Group | 2021-06-02 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (NCT04541225) | Nuvation Bio Inc. | 2020-12-08 |
| Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone (NCT04296578) | Stanford University | 2020-10-01 |
| LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer (NCT04053062) | Bioray Laboratories | 2020-07-16 |
| Checkpoint Inhibitors and SBRT for MCRPC (NCT05655715) | Herlev and Gentofte Hospital | 2019-11-25 |
| Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223 (NCT04995614) | Radboud University Medical Center | 2017-04-01 |
| Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor (NCT02814669) | Hoffmann-La Roche | 2016-09-23 |
| A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) (NCT02259114) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-10-23 |
| Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer (NCT01832870) | Prostate Oncology Specialists, Inc. | 2013-04-01 |
| A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer (NCT01717898) | Charles Ryan | 2013-01-31 |
| A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) (NCT01907009) | Barts & The London NHS Trust | 2013-01-01 |
| Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer (NCT01599793) | University of Chicago | 2012-05-01 |
| Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer (NCT01313559) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-06-01 |
| Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients (NCT01352208) | Astellas Pharma Inc | 2011-03-01 |
| Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer (NCT01824342) | Amgen | 2011-01-01 |
| PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy (NCT01144897) | Daniel Vaena | 2010-05-01 |
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) (NCT01083615) | Achieve Life Sciences | 2010-03-01 |
| Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer (NCT00838201) | Amgen | 2009-02-01 |
| AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer (NCT00770848) | Amgen | 2008-11-01 |